Otsuka Pakistan Limited (PSX:OTSU)

Market Cap	3.51B
Revenue (ttm)	3.69B
Net Income (ttm)	31.27M
Shares Out	12.10M
EPS (ttm)	2.59
PE Ratio	112.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,687
Average Volume	18,410
Open	294.50
Previous Close	292.09
Day's Range	287.00 - 301.00
52-Week Range	117.50 - 478.89
Beta	0.68
RSI	55.68
Earnings Date	Aug 27, 2025

About Otsuka Pakistan

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, w...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 345
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: OTSU

Financial Performance

In 2024, Otsuka Pakistan's revenue was 3.16 billion, an increase of 4.24% compared to the previous year's 3.04 billion. Losses were -4.76 million, -33.91% less than in 2023.